MX2009012381A - Composicion antigenica liofilizada. - Google Patents
Composicion antigenica liofilizada.Info
- Publication number
- MX2009012381A MX2009012381A MX2009012381A MX2009012381A MX2009012381A MX 2009012381 A MX2009012381 A MX 2009012381A MX 2009012381 A MX2009012381 A MX 2009012381A MX 2009012381 A MX2009012381 A MX 2009012381A MX 2009012381 A MX2009012381 A MX 2009012381A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- lyophilised
- antigen composition
- lyophilised antigen
- immunogenic compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 102000002689 Toll-like receptor Human genes 0.000 abstract 2
- 108020000411 Toll-like receptor Proteins 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona composiciones liofilizadas que comprenden un antígeno y un agonista del receptor de tipo TolI (TLR) 9. Tales composiciones se pueden reconstituir en composiciones inmunogénicas para uso en vacunación con un vehículo seleccionado entre el grupo de vehículos particulados constituidos por liposomas, sales minerales, emulsiones, polímeros e ISCOM. Los procedimientos de preparación de composiciones inmunogénicas a partir de composiciones liofilizadas de la invención y uso de la misma en la inmunización también se proporcionan en el presente documento.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2007/055037 WO2007137986A2 (en) | 2006-05-26 | 2007-05-24 | Vaccination against cancer |
GB0723044A GB0723044D0 (en) | 2007-11-23 | 2007-11-23 | Lyophillised antigen composition |
GB0723900A GB0723900D0 (en) | 2007-12-06 | 2007-12-06 | Lyophillised antigen composition |
PCT/EP2008/056305 WO2008142133A1 (en) | 2007-05-24 | 2008-05-22 | Lyophilised antigen composition |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009012381A true MX2009012381A (es) | 2009-12-01 |
Family
ID=39714209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009012381A MX2009012381A (es) | 2007-05-24 | 2008-05-22 | Composicion antigenica liofilizada. |
Country Status (23)
Country | Link |
---|---|
US (2) | US20090035360A1 (es) |
EP (3) | EP2148697B1 (es) |
JP (1) | JP5331105B2 (es) |
KR (2) | KR101238795B1 (es) |
CN (1) | CN101678091A (es) |
AR (1) | AR066676A1 (es) |
AU (1) | AU2008252911B2 (es) |
BR (1) | BRPI0811228A2 (es) |
CA (1) | CA2687632C (es) |
CL (1) | CL2008001491A1 (es) |
CY (1) | CY1113446T1 (es) |
DK (1) | DK2148697T3 (es) |
EA (3) | EA201300101A1 (es) |
ES (1) | ES2395333T3 (es) |
HR (1) | HRP20121019T1 (es) |
MX (1) | MX2009012381A (es) |
PE (1) | PE20090281A1 (es) |
PL (1) | PL2148697T3 (es) |
PT (1) | PT2148697E (es) |
SI (1) | SI2148697T1 (es) |
TW (1) | TW200911304A (es) |
UY (1) | UY31101A1 (es) |
WO (1) | WO2008142133A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200726479A (en) | 2005-04-12 | 2007-07-16 | Univ Duke | Method of inducing neutralizing antibodies to human immunodeficiency virus |
EP1951281B1 (en) | 2005-10-17 | 2015-04-15 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
US9265816B2 (en) | 2006-04-10 | 2016-02-23 | Sloan Kettering Institute For Cancer Research | Immunogenic WT-1 peptides and methods of use thereof |
EP2139516A4 (en) * | 2007-04-13 | 2011-06-29 | Univ Duke | METHOD FOR INDUCING NEUTRALIZING ANTIBODIES AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS |
AU2010232915A1 (en) * | 2009-04-03 | 2011-10-20 | Duke University | Formulation for inducing broadly reactive neutralizing anti-HIV antibodies |
GB0910046D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
GB0910045D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
PT3023106T (pt) | 2010-12-14 | 2019-11-04 | Glaxosmithkline Biologicals Sa | Composição antigénica de micobactéria |
MX2014000893A (es) * | 2011-07-22 | 2014-05-30 | Glaxosmithkline Biolog Sa | Purificacion del antigeno expresado preferentemente en melanoma. |
US20150104413A1 (en) | 2012-01-13 | 2015-04-16 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
HUE052541T2 (hu) | 2013-01-15 | 2021-05-28 | Memorial Sloan Kettering Cancer Center | Immunogén WT-1 peptidek és eljárások azok alkalmazására |
US10076567B2 (en) | 2013-09-27 | 2018-09-18 | Duke University | MPER-liposome conjugates and uses thereof |
PT3089754T (pt) * | 2013-12-31 | 2021-07-23 | Infectious Disease Res Inst | Formulações de vacina de dose única |
CA2943050A1 (en) * | 2014-03-25 | 2015-10-01 | The Government Of The United States Of America As Represented By The Secretary Of The Army | Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines |
SG10202012205XA (en) | 2015-11-06 | 2021-01-28 | Adjuvance Technologies Inc | Triterpene saponin analogues |
CN110035770B (zh) | 2016-12-07 | 2023-06-16 | 葛兰素史密丝克莱恩生物有限公司 | 新方法 |
SG11202001826YA (en) * | 2017-10-16 | 2020-03-30 | Adjuvance Technologies Inc | Triterpene saponin analogues |
WO2020016322A1 (en) | 2018-07-19 | 2020-01-23 | Glaxosmithkline Biologicals Sa | Processes for preparing dried polysaccharides |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5827A (en) | 1848-10-03 | Improved table-cutlery | ||
US666A (en) | 1838-04-02 | Sfbing-bock for coagh and railroad-gab | ||
ATE160361T1 (de) | 1987-01-07 | 1997-12-15 | Imp Cancer Res Tech | Humane polymorphe epitheliale mucin polypeptide zur verwendung in therapie und diagnose |
US6054438A (en) | 1987-01-07 | 2000-04-25 | Imperial Cancer Research Technology Limited | Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin |
US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4963484A (en) * | 1988-01-29 | 1990-10-16 | Dana-Farber Cancer Institute, Inc. | Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen |
US5278302A (en) * | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5256643A (en) * | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
US5744144A (en) | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
US5688506A (en) | 1994-01-27 | 1997-11-18 | Aphton Corp. | Immunogens against gonadotropin releasing hormone |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
WO1996002555A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US5830753A (en) * | 1994-09-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. |
US5981215A (en) | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
US5666153A (en) * | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
US6130043A (en) | 1997-05-02 | 2000-10-10 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
JP2001517638A (ja) * | 1997-09-25 | 2001-10-09 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | 小細胞肺癌に対するフコーシルgm−1−klh接合体ワクチン |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
AU4823599A (en) | 1998-06-22 | 2000-01-10 | Incyte Pharmaceuticals, Inc. | Prostate cancer-associated genes |
DE69929444T2 (de) * | 1998-08-10 | 2006-09-28 | Antigenics Inc., Woburn | Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung |
US20030235557A1 (en) * | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
WO2000044899A1 (en) | 1999-01-29 | 2000-08-03 | Corixa Corporation | Her-2/neu fusion proteins |
HUP0200366A2 (en) | 1999-03-11 | 2002-06-29 | Smithkline Beecham Biolog | Novel compounds |
US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
DK1265915T3 (da) | 2000-02-23 | 2011-02-14 | Glaxosmithkline Biolog Sa | Nye forbindelser |
US20040022814A1 (en) * | 2000-06-15 | 2004-02-05 | O'hagan Derek | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
GB0022742D0 (en) * | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
JP2004509970A (ja) | 2000-09-26 | 2004-04-02 | ハイブリドン・インコーポレイテッド | 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節 |
US20030031684A1 (en) | 2001-03-30 | 2003-02-13 | Corixa Corporation | Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA) |
US7553494B2 (en) * | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
EP1427826B1 (en) | 2001-09-20 | 2011-04-20 | Glaxo Group Limited | HIV- RT-nef-Gag codon optimised DNA vaccines |
WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
GB0218821D0 (en) * | 2002-08-13 | 2002-09-18 | Glaxosmithkline Biolog Sa | Novel compositions |
EP1575611A4 (en) * | 2002-12-23 | 2007-10-03 | Hope City | VACCINIA ANKARA MODIFIED EXPRESSING P53 IN IMMUNOTHERAPY OF CANCER |
GB0323968D0 (en) | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
EP1547581A1 (en) * | 2003-12-23 | 2005-06-29 | Vectron Therapeutics AG | Liposomal vaccine for the treatment of human hematological malignancies |
GB0409940D0 (en) * | 2004-05-04 | 2004-06-09 | Glaxosmithkline Biolog Sa | Vaccine |
GB0411411D0 (en) | 2004-05-21 | 2004-06-23 | Glaxosmithkline Biolog Sa | Vaccines |
JP2008502732A (ja) * | 2004-06-12 | 2008-01-31 | ファーマ パシフィック プロプリエタリイ リミテッド | ワクチンに対する免疫応答を増強する方法 |
GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
WO2006092017A1 (en) | 2005-03-02 | 2006-09-08 | Solbec Pharmaceuticals Limited | Glycoalkaloid and tlr agonist combinations and various uses thereof |
EP2385060A3 (en) * | 2005-06-17 | 2012-02-15 | Mannkind Corporation | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
-
2008
- 2008-05-22 US US12/125,182 patent/US20090035360A1/en not_active Abandoned
- 2008-05-22 EA EA201300101A patent/EA201300101A1/ru unknown
- 2008-05-22 AU AU2008252911A patent/AU2008252911B2/en not_active Ceased
- 2008-05-22 CA CA2687632A patent/CA2687632C/en not_active Expired - Fee Related
- 2008-05-22 AR ARP080102167A patent/AR066676A1/es not_active Application Discontinuation
- 2008-05-22 EA EA201300102A patent/EA201300102A1/ru unknown
- 2008-05-22 KR KR1020097025005A patent/KR101238795B1/ko not_active IP Right Cessation
- 2008-05-22 PL PL08759906T patent/PL2148697T3/pl unknown
- 2008-05-22 BR BRPI0811228-2A2A patent/BRPI0811228A2/pt not_active IP Right Cessation
- 2008-05-22 TW TW097119008A patent/TW200911304A/zh unknown
- 2008-05-22 CN CN200880017245A patent/CN101678091A/zh active Pending
- 2008-05-22 DK DK08759906.4T patent/DK2148697T3/da active
- 2008-05-22 ES ES08759906T patent/ES2395333T3/es active Active
- 2008-05-22 MX MX2009012381A patent/MX2009012381A/es active IP Right Grant
- 2008-05-22 PE PE2008000879A patent/PE20090281A1/es not_active Application Discontinuation
- 2008-05-22 EP EP08759906A patent/EP2148697B1/en not_active Not-in-force
- 2008-05-22 EP EP12157796A patent/EP2476431A1/en not_active Withdrawn
- 2008-05-22 EA EA200901434A patent/EA018201B1/ru not_active IP Right Cessation
- 2008-05-22 KR KR1020117016237A patent/KR20110091817A/ko not_active Application Discontinuation
- 2008-05-22 UY UY31101A patent/UY31101A1/es unknown
- 2008-05-22 CL CL2008001491A patent/CL2008001491A1/es unknown
- 2008-05-22 WO PCT/EP2008/056305 patent/WO2008142133A1/en active Application Filing
- 2008-05-22 PT PT87599064T patent/PT2148697E/pt unknown
- 2008-05-22 EP EP20120157797 patent/EP2489367A1/en not_active Withdrawn
- 2008-05-22 SI SI200830836T patent/SI2148697T1/sl unknown
- 2008-05-22 JP JP2010508850A patent/JP5331105B2/ja not_active Expired - Fee Related
-
2010
- 2010-11-15 US US12/946,171 patent/US8557247B2/en not_active Expired - Fee Related
-
2012
- 2012-12-10 CY CY20121101196T patent/CY1113446T1/el unknown
- 2012-12-12 HR HRP20121019AT patent/HRP20121019T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009012381A (es) | Composicion antigenica liofilizada. | |
MX2013001527A (es) | Nuevas vacunas adyuvantes en base a adyuvantes de orientacion para anticuerpos directamente hacia celulas presentadoras de antigenos. | |
GB201009273D0 (en) | Novel vaccine | |
GB0428394D0 (en) | Saccharide conjugate vaccines | |
EP2554571A4 (en) | HYDROXY TERMINATED SILOXANE, POLYSILOXANE-POLYCARBONATE COPOLYMER, AND THEIR SYNTHESIS METHODS | |
NZ582822A (en) | Novel immunogenic epitopes for immunotherapy | |
MX2013013111A (es) | Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma. | |
WO2007116409A8 (en) | Improved vaccines comprising multimeric hsp60 peptide carriers | |
WO2005037190A3 (en) | Multiplex vaccines | |
PT2468300T (pt) | Composição para vacina contendo adjuvante sintético | |
WO2010104747A3 (en) | Antigen presenting cell targeted vaccines | |
MX2013013924A (es) | Composicion inmunogenica. | |
WO2008127296A3 (en) | Methods and compositions for treating tularemia | |
IN2014CN03454A (es) | ||
MY180699A (en) | Toll-like receptor 3 antagonists | |
TN2009000195A1 (en) | Prime boost canine leishmania vaccine | |
WO2011140634A3 (en) | The n-domain of carcinoembryonic antigen and compositions, methods and uses thereof | |
TNSN08184A1 (en) | Chimeric antigens and vaccines | |
WO2014022835A3 (en) | PEPTIDE VACCINES BASED ON THE EGFRvIII SEQUENCE FOR THE TREATMENT OF TUMORS | |
WO2009129498A3 (en) | Substance p and analogs thereof as a cancer immunogenic composition adjuvant | |
MX2009011851A (es) | Plasmidos de dna que tienen expresion y estabilidad mejoradas. | |
TH87147B (th) | วัคซีนสำหรับการทำให้เกิดภูมิคุ้มกันที่ต้านเชื้อเฮลิโคแมคเตอร์ | |
WO2008100142A3 (en) | Vaccine formulation | |
NZ717726A (en) | Anti-αβtcr antibody | |
MX2013006326A (es) | Composiciones y metodos para vacunar ganado vacuno. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |